Efinopegdutide + Semaglutide + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Trial Timeline
Jun 23, 2023 → Dec 29, 2025
NCT ID
NCT05877547About Efinopegdutide + Semaglutide + Placebo
Efinopegdutide + Semaglutide + Placebo is a phase 2 stage product being developed by Merck for Non-alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05877547. Target conditions include Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD.
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Fatty Liver Disease were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05877547 | Phase 2 | Completed |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease